# The Efficacy and Safety of Faster Insulin Aspart (Fiasp®) Compared to Conventional Insulin Aspart (NovoLog®) as Correction Bolus

> **NCT04414579** · PHASE4 · UNKNOWN · sponsor: **Mountain Diabetes and Endocrine Center** · enrollment: 45 (estimated)

## Conditions studied

- Type 1 Diabetes Mellitus

## Interventions

- **DRUG:** Faster Insulin Aspart (Fiasp®)

## Key facts

- **NCT ID:** NCT04414579
- **Lead sponsor:** Mountain Diabetes and Endocrine Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-03-27
- **Primary completion:** 2021-03
- **Final completion:** 2021-03
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2020-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04414579

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04414579, "The Efficacy and Safety of Faster Insulin Aspart (Fiasp®) Compared to Conventional Insulin Aspart (NovoLog®) as Correction Bolus". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04414579. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*